CEL SCI CORP CVM
CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine:
Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and
L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.
Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review under CEL-SCI's future anticipated regulatory submission for approval. None of CEL-SCI's product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $15.9M | $18.2M | $22.5M | $25.4M | $23.1M | $17.8M | $12.7M | $10.9M | $15.6M | $17.4M |
| SG&A | $8.9M | $8.2M | $9.0M | $10.7M | $13.1M | $11.7M | $8.0M | $6.3M | $5.8M | $6.5M |
| Total operating expenses | $24.8M | $26.4M | $31.5M | $36.1M | $36.2M | $29.5M | $20.7M | $17.2M | $21.4M | $23.9M |
| Operating income | -$24.8M | -$26.4M | -$31.5M | -$36.1M | -$36.2M | -$29.0M | -$20.2M | -$16.8M | -$21.4M | -$23.6M |
| Interest expense | $649.0K | $746.0K | $675.4K | $1.1M | $1.1M | $1.0M | $1.8M | — | — | $1.9M |
| Pre-tax income | — | — | — | — | — | -$30.3M | -$22.1M | — | — | — |
| Net income | -$25.4M | -$26.9M | -$32.4M | -$36.7M | -$36.4M | -$30.3M | -$22.1M | -$31.8M | -$14.4M | -$11.5M |
| EPS, basic | — | — | — | -0.87 | -0.90 | -0.82 | -0.71 | -1.87 | -1.83 | -2.37 |
| EPS, diluted | -6.27 | -15.31 | -0.73 | -0.87 | -0.90 | -0.82 | -0.71 | -1.87 | -1.91 | -2.37 |
| Shares, diluted (wtd. avg.) | 4.1M | 1.8M | 44.5M | 43.1M | 40.7M | 36.8M | 31.2M | 17.0M | 7.9M | 4.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.0M | $4.7M | $4.1M | $22.7M | $36.1M | $15.5M | $8.4M | $10.3M | $2.4M | $2.9M |
| Short-term investments | — | — | — | $0 | $6.2M | $0 | — | — | — | — |
| Receivables | — | — | — | $0 | $54.9K | $54.9K | $62.8K | $118.7K | $218.5K | $394.5K |
| Inventory | — | $1.0M | $2.2M | $2.0M | $2.0M | $820.1K | $782.4K | $645.2K | $672.5K | $1.0M |
| Total current assets | $11.6M | $6.1M | $6.9M | $25.4M | $45.3M | $17.7M | $9.8M | $11.4M | $4.2M | $5.5M |
| Property, plant and equipment | $6.1M | $8.1M | $10.2M | $11.9M | $13.7M | $5.8M | $15.8M | $16.2M | $16.8M | $17.4M |
| Other intangibles | $119.9K | $165.5K | $197.7K | $212.2K | $275.9K | — | $311.6K | $258.1K | $223.2K | $256.5K |
| Total assets | $28.2M | $27.0M | $30.5M | $50.5M | $75.9M | $40.5M | $27.6M | $29.6M | $22.9M | $24.9M |
| Accounts payable | $1.1M | $1.4M | $2.0M | $1.6M | $1.7M | $2.0M | $1.6M | $5.7M | $8.2M | $3.1M |
| Total current liabilities | $5.1M | $4.6M | $5.6M | $4.7M | $3.9M | $4.3M | $3.0M | $9.2M | $10.8M | $4.0M |
| Total liabilities | $12.2M | $14.1M | $17.3M | $18.4M | $19.3M | $20.8M | $22.5M | $29.6M | $26.3M | $25.6M |
| Retained earnings | -$539.4M | -$514.0M | -$487.1M | -$454.9M | -$418.2M | -$381.8M | -$353.7M | -$331.6M | -$299.8M | -$285.4M |
| Total equity | $16.0M | $12.9M | $13.2M | $32.2M | $56.5M | $19.7M | $5.1M | $916 | -$3.3M | -$679.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.1M | -$18.8M | -$22.8M | -$18.2M | -$18.8M | -$15.3M | -$16.3M | -$13.4M | -$13.8M | -$23.1M |
| Depreciation and amortisation | $2.1M | $2.1M | $2.1M | $2.0M | $447.0K | $389.0K | $588.0K | $575.0K | $593.0K | $626.0K |
| Stock-based compensation | $1.9M | $4.3M | $6.3M | $11.4M | $13.7M | $10.1M | $4.4M | $2.7M | $1.4M | $2.1M |
| Capital expenditure | $38.1K | $94.9K | $361.9K | $637.9K | $9.0M | $2.7M | $177.8K | $1.0K | $10.5K | $31.4K |
| Investing cash flow | -$38.1K | -$108.1K | -$372.3K | $5.5M | -$15.2M | -$2.7M | -$335.8K | -$58.1K | -$17.0K | -$34.2K |
| Financing cash flow | $23.4M | $19.5M | $4.7M | -$638.4K | $54.5M | $25.0M | $14.8M | $21.4M | $13.3M | $20.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001654954-25-014303.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$11.5M | -$14.4M | -$31.8M | -$22.1M | -$30.3M | -$36.4M | -$36.7M | -$32.4M | -$26.9M | -$25.4M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Shareholder rights changed Item 3.03
- Material agreement signed Item 1.01
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |